<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03570632</url>
  </required_header>
  <id_info>
    <org_study_id>PRO18050459</org_study_id>
    <nct_id>NCT03570632</nct_id>
  </id_info>
  <brief_title>Metformin for Preeclampsia Prevention in Pregnant Women With Type 1 Diabetes Mellitus</brief_title>
  <official_title>Metformin for Preeclampsia Prevention in Pregnant Women With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maisa N. Feghali, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although major advancements have been made in improving glycemic management in type 1
      diabetes mellitus (DM), women entering pregnancy with type 1 DM continue to be at
      dramatically increased risk for adverse maternal and neonatal outcomes, including
      hypertensive disorders of pregnancy (HDP). At present, there is a lack of effective
      preventive interventions for HDP, which are associated with significant maternal and neonatal
      morbidity and mortality. Clinical and in vitro data have shown promise for metformin in
      prevention of HDP in non-diabetic women. Metformin has a reassuring fetal safety profile and
      has been well studied in type 1 DM outside of pregnancy. The hypothesis to be tested in this
      application is that compared to usual care, daily oral metformin therapy initiated prior to
      20 weeks' gestation in women with type 1 DM reduces the frequency of HDP.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of hypertensive disorders of pregnancy</measure>
    <time_frame>Delivery/End of pregnancy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Home glucose levels throughout pregnancy</measure>
    <time_frame>Weekly, throughout pregnancy from enrollment to delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birthweight</measure>
    <time_frame>Delivery/End of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal morbidity</measure>
    <time_frame>Delivery/End of pregnancy</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Gestational weight gain</measure>
    <time_frame>At time of prenatal visits, throughout pregnancy from enrollment to delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Umbilical cord c-peptide</measure>
    <time_frame>Delivery/End of pregnancy</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Umbilical cord glucose</measure>
    <time_frame>Delivery/End of pregnancy</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Neonatal body composition</measure>
    <time_frame>Delivery/End of pregnancy</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Pregnancy in Diabetes</condition>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Participants randomized to metformin will receive metformin in addition to standard treatment of diabetes during pregnancy</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women 18-50 years

          -  12 0/7 and 19 6/7 weeks of gestation

          -  Diagnosed with type 1 DM prior to pregnancy.

        Exclusion Criteria:

          -  Known allergy or adverse reaction to metformin

          -  Multiple gestation

          -  Abnormal obstetrical ultrasound suspicious for major congenital abnormality, known or
             suspected fetal aneuploidy

          -  Medical comorbidities that increase risk for metformin use: renal insufficiency
             (creatinine &gt; 1.1 mg/dL), proteinuria (P:C &gt;0.3 or 24-hour urine protein &gt; 300 mg),
             active liver disease (acute hepatitis, chronic active hepatitis, persistently abnormal
             liver enzymes 3x above normal), inflammatory bowel disease (Crohn's and Ulcerative
             colitis), major hematologic disorder (including alloimmune and isoimmune
             thrombocytopenia).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only pregnant women are eligible to participate in the study</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maisa N Feghali, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maisa N Feghali, MD</last_name>
    <phone>4126471000</phone>
    <email>feghalim@upmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Magee Womens Hospital of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maisa Feghali, MD</last_name>
      <phone>412-647-1000</phone>
      <email>feghalim@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Maisa Feghali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 15, 2018</study_first_submitted>
  <study_first_submitted_qc>June 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2018</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Maisa N. Feghali, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Pregnancy in Diabetics</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

